Loading...

Urovant Sciences Ltd ($UROV)

Stock Image

UROV Overview

Urovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States.The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome.It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017.Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. (From: StockAnalysis.com)

MORE ABOUT Urovant Sciences Ltd

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.